Physician profile

Jeffrey D Hyde

Interventional Cardiology · Baton Rouge, LA

NPI 1336143841

$4,213.22

in general payments reported to CMS, 2019-2025

43 companies · $525 in 2025

The $525 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,503.80
Education$20.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $595.48 2019-2025
Amgen INC. $409.87 2019-2025 Repatha, Repatha
Janssen Pharmaceuticals, INC $401.30 2019-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $325.76 2019-2025 Lifevest
Medtronic Vascular, INC. $317.21 2019-2020
Pfizer INC. $215.69 2019-2024
Merck Sharp & Dohme LLC $164.77 2023-2025 Verquvo, Capvaxive
Cleerly, INC. $162.34 2025 Cleerly Labs, Cleerly Ischemia
Abiomed $135.36 2019-2025 Impella
Astrazeneca Pharmaceuticals LP $123.56 2019-2024 Farxiga
E.R. Squibb & Sons, L.L.C. $119.63 2019-2024 Camzyos, Eliquis
Amarin Pharma, INC. $98.57 2019-2021
Kestra Medical Technology Services, INC. $84.35 2022-2025 Assure Wcd
Chiesi USA, INC. $76.67 2020-2021
Ethicon US, LLC $74.66 2019
Show all 43 companies
CompanyGeneral paymentsYearsTop products
W. L. Gore & Associates, INC. $66.66 2019
Lundbeck LLC $55.32 2019-2020
Esperion Therapeutics, INC. $55.27 2020-2024 Nexletol
Abbott Laboratories $48.25 2019-2021
Kiniksa Pharmaceuticals, LTD. $47.35 2022-2023 Arcalyst
Celonova Biosciences, INC. $42.71 2019
Baxter Healthcare $40.94 2022-2025 Hillrom - Carnation Ambulatory Monitor
Novo Nordisk INC $39.66 2025 Wegovy
Boehringer Ingelheim Pharmaceuticals, INC. $37.95 2023-2025 Jardiance
Kiniksa Pharmaceuticals International, Plc $37.55 2024 Arcalyst
Arbor Pharmaceuticals, INC. $36.19 2019
Bayer Healthcare Pharmaceuticals INC. $35.60 2021-2025
Sanofi-Aventis U.S. LLC $34.47 2019
Boston Scientific Corporation $34.07 2023-2024 Watchman Access System, Watchman Flx
Atricure, INC. $28.66 2024
Astellas Pharma US INC $24.95 2020
Edwards Lifesciences Corporation $24.63 2019
Gilead Sciences, INC. $23.98 2019
Alnylam Pharmaceuticals INC. $23.82 2020
Irhythm Technologies, INC. $22.68 2023 Zio Xt Patch
Kowa Pharmaceuticals America, INC. $22.10 2019
Genzyme Corporation $21.30 2024
Actelion Pharmaceuticals US, INC. $20.98 2024 Uptravi, Opsumit
Biogen, INC. $19.47 2024 Skyclarys
Lexicon Pharmaceuticals, INC. $18.38 2023 Inpefa
Heartflow, INC. $17.84 2025
Scpharmaceuticals INC. $14.08 2025
Regeneron Healthcare Solutions, INC. $13.14 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jeffrey D Hyde

$4,213.22

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $525 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/15222/jeffrey-d-hyde

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.